Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases

Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not well mapped in cancer. Patient-derived organoids (PDOs) may predict clinical drug responses ex vivo and offer an opportunity to evaluate novel treatment strategies in a personalized fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kryeziu, Kushtrim, Moosavi, Seyed H., Bergsland, Christian H., Guren, Marianne G., Eide, Peter W., Totland, Max Z., Lassen, Kristoffer, Abildgaard, Andreas, Nesbakken, Arild, Sveen, Anita, Lothe, Ragnhild A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424985/
https://www.ncbi.nlm.nih.gov/pubmed/34496878
http://dx.doi.org/10.1186/s12967-021-03062-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424985/
https://www.ncbi.nlm.nih.gov/pubmed/34496878
http://dx.doi.org/10.1186/s12967-021-03062-3

Ejemplares similares